To investigate the anti-hepatocellular carcinoma (HCC) activity of Gitogenin (Gito) and its underlying mechanisms.
Approach:
In vitro and in vivo experiments: Conducted MTT assay, colony formation assay, immunofluorescence staining, Western blot, wound healing assay, Transwell migration and invasion assays, and patient-derived xenograft (PDX) mouse models.
Key Findings:
Gito suppressed HCC growth and progression by promoting autophagy and inhibiting epithelial-mesenchymal transition (EMT) and metastasis.
The NUAK2/NF-κB signaling pathway was identified as a key mechanism through which Gito exerts its effects.
Inhibition of autophagy reduced Gito's effects on EMT, invasion, and migration of HCC cells.
Overexpression of NUAK2 diminished Gito's inhibitory effects on EMT, migration, and invasion.
Interpretation:
Gito may function as a potential inhibitor of NUAK2, providing a basis for its role in regulating autophagy and metastatic abilities of HCC cells.
Limitations:
The study primarily focuses on in vitro and in vivo models, which may not fully replicate human HCC conditions.
Further research is needed to validate the clinical relevance of Gito in HCC treatment.
Conclusion:
Gito shows promise as a candidate drug for HCC treatment by targeting the NUAK2/NF-κB axis.
